1
|
Ariga T. The Pathogenic Role of Ganglioside Metabolism in Alzheimer's Disease-Cholinergic Neuron-Specific Gangliosides and Neurogenesis. Mol Neurobiol 2018; 54:623-638. [PMID: 26748510 DOI: 10.1007/s12035-015-9641-0] [Citation(s) in RCA: 23] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Abstract
Alzheimer's disease (AD) is the most common type of dementia with clinical symptoms that include deficits in memory, judgment, thinking, and behavior. Gangliosides are present on the outer surface of plasma membranes and are especially abundant in the nervous tissues of vertebrates. Ganglioside metabolism, especially the cholinergic neuron-specific gangliosides, GQ1bα and GT1aα, is altered in mouse model of AD and patients with AD. Thus, alterations in ganglioside metabolism may participate in several events related to the pathogenesis of AD. Increased expressions of GT1aα may reflect cholinergic neurogenesis. Most changes in ganglioside metabolism occur in the specific brain areas and their lipid rafts. Targeting ganglioside metabolism in lipid rafts may represent an underexploited opportunity to design novel therapeutic strategies for AD.
Collapse
Affiliation(s)
- Toshio Ariga
- Department of Neuroscience and Regenerative Medicine, Institute of Neuroscience, Medical College of Georgia, Augusta University, Augusta, GA, 30912, USA. .,Department of Materials and Applied Chemistry, College of Science and Technology, Nihon University, Chiyoda-ku, Tokyo, 101-8308, Japan.
| |
Collapse
|
2
|
Lowrance SA, Fink KD, Crane A, Matyas J, Dey ND, Matchynski JJ, Thibo T, Reinke T, Kippe J, Hoffman C, Sandstrom M, Rossignol J, Dunbar GL. Bone-marrow-derived mesenchymal stem cells attenuate cognitive deficits in an endothelin-1 rat model of stroke. Restor Neurol Neurosci 2016; 33:579-88. [PMID: 23902985 DOI: 10.3233/rnn-130329] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/01/2023]
Abstract
PURPOSE Stroke is the third leading cause of death and permanent disability in the United States, often producing long-term cognitive impairments, which are not easily recapitulated in animal models. The goals of this study were to assess whether: (1) the endothelin-1 (ET-1) model of chronic stroke produced discernable cognitive deficits; (2) a spatial operant reversal task (SORT) would accurately measure memory deficits in this model; and (3) bone-marrow-derived mesenchymal stem cells (BMMSCs) could reduce any observed deficits. METHODS Rats were given unilateral intracerebral injections of vehicle or ET-1, a stroke-inducing agent, near the middle cerebral artery. Seven days later, they were given intrastriatal injections of BMMSCs or vehicle, near the ischemic penumbra. The cognitive abilities of the rats were assessed on a novel SORT, which was designed to efficiently distinguish cognitive deficits from potential motoric confounds. RESULTS Rats given ET-1 had significantly more cognitive errors at six weeks post-stroke on the SORT, and that these deficits were attenuated by BMMSC transplants. CONCLUSIONS These findings indicate that: (1) the ET-1 model produces chronic cognitive deficits; (2) the SORT efficiently measures cognitive deficits that are not confounded by motoric impairment; and (3) BMMSCs may be a viable treatment for stroke-induced cognitive dysfunction.
Collapse
Affiliation(s)
- S A Lowrance
- Field Neurosciences Institute Laboratory for Restorative Neurology, Mount Pleasant, MI, USA.,Central Michigan University Program in Neuroscience, Mount Pleasant, MI, USA
| | - K D Fink
- Field Neurosciences Institute Laboratory for Restorative Neurology, Mount Pleasant, MI, USA.,Central Michigan University Program in Neuroscience, Mount Pleasant, MI, USA
| | - A Crane
- Field Neurosciences Institute Laboratory for Restorative Neurology, Mount Pleasant, MI, USA.,Central Michigan University Program in Neuroscience, Mount Pleasant, MI, USA
| | - J Matyas
- Field Neurosciences Institute Laboratory for Restorative Neurology, Mount Pleasant, MI, USA.,Central Michigan University Program in Neuroscience, Mount Pleasant, MI, USA
| | - N D Dey
- Field Neurosciences Institute, Saginaw, MI, USA
| | - J J Matchynski
- Field Neurosciences Institute Laboratory for Restorative Neurology, Mount Pleasant, MI, USA.,Central Michigan University Program in Neuroscience, Mount Pleasant, MI, USA
| | - T Thibo
- Field Neurosciences Institute Laboratory for Restorative Neurology, Mount Pleasant, MI, USA.,Central Michigan University Program in Neuroscience, Mount Pleasant, MI, USA
| | - T Reinke
- Field Neurosciences Institute Laboratory for Restorative Neurology, Mount Pleasant, MI, USA.,Central Michigan University Program in Neuroscience, Mount Pleasant, MI, USA
| | - J Kippe
- Field Neurosciences Institute Laboratory for Restorative Neurology, Mount Pleasant, MI, USA.,Central Michigan University Program in Neuroscience, Mount Pleasant, MI, USA
| | - C Hoffman
- Field Neurosciences Institute Laboratory for Restorative Neurology, Mount Pleasant, MI, USA.,Central Michigan University Program in Neuroscience, Mount Pleasant, MI, USA
| | - M Sandstrom
- Central Michigan University Program in Neuroscience, Mount Pleasant, MI, USA
| | - J Rossignol
- Field Neurosciences Institute Laboratory for Restorative Neurology, Mount Pleasant, MI, USA.,Central Michigan University Program in Neuroscience, Mount Pleasant, MI, USA.,Central Michigan University College of Medicine, Mount Pleasant, MI, USA
| | - G L Dunbar
- Field Neurosciences Institute Laboratory for Restorative Neurology, Mount Pleasant, MI, USA.,Central Michigan University Program in Neuroscience, Mount Pleasant, MI, USA.,Field Neurosciences Institute, Saginaw, MI, USA
| |
Collapse
|
3
|
Matchynski-Franks JJ, Pappas C, Rossignol J, Reinke T, Fink K, Crane A, Twite A, Lowrance SA, Song C, Dunbar GL. Mesenchymal Stem Cells as Treatment for Behavioral Deficits and Neuropathology in the 5xFAD Mouse Model of Alzheimer's Disease. Cell Transplant 2016; 25:687-703. [DOI: 10.3727/096368916x690818] [Citation(s) in RCA: 19] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/23/2022] Open
Abstract
Alzheimer's disease (AD) is characterized by a progressive loss of memory and other cognitive disturbances. The neuropathology of AD includes the major hallmarks of toxic amyloid-β oligomer accumulation and neurofibrillary tangles, as well as increased oxidative stress, cholinergic dysfunction, synapse loss, changes in endogenous neurotrophic factors, and overall degeneration of the brain. Adult mesenchymal stem cells (MSCs) offer the potential for a readily available treatment that would be long lasting, have low likelihood of rejection, and could target a variety of pathological deficits. MSCs have been shown to be effective in alleviating symptoms in some transgenic models of AD, but the optimal location for transplanting MSCs has yet to be determined. In the present study, the behavioral effects of transplantation of MSCs into the lateral ventricles, the hippocampus, or both of these regions were compared in the 5xFAD mouse model of AD. The results indicate that MSC transplants effectively reduce learning deficits in the 5xFAD mouse model and demonstrate a clear impact of MSCs on the levels of Aβ42 in the brains of 5xFAD mice. Overall, these findings support the hypothesis that MSCs may be a viable treatment for AD, especially when injected into the lateral ventricles.
Collapse
Affiliation(s)
- Jessica J. Matchynski-Franks
- Field Neurosciences Laboratory for Restorative Neurology, Central Michigan University, Mt. Pleasant, MI, USA
- Program in Neuroscience, Central Michigan University, Mt. Pleasant, MI, USA
- Department of Psychology and Behavioral Sciences, Rochester College, Rochester Hills, MI, USA
| | - Colleen Pappas
- Field Neurosciences Laboratory for Restorative Neurology, Central Michigan University, Mt. Pleasant, MI, USA
- Program in Neuroscience, Central Michigan University, Mt. Pleasant, MI, USA
| | - Julien Rossignol
- Field Neurosciences Laboratory for Restorative Neurology, Central Michigan University, Mt. Pleasant, MI, USA
- Program in Neuroscience, Central Michigan University, Mt. Pleasant, MI, USA
- College of Medicine, Central Michigan University, Mt. Pleasant, MI, USA
| | - Tiffany Reinke
- Field Neurosciences Laboratory for Restorative Neurology, Central Michigan University, Mt. Pleasant, MI, USA
- Program in Neuroscience, Central Michigan University, Mt. Pleasant, MI, USA
| | - Kyle Fink
- Field Neurosciences Laboratory for Restorative Neurology, Central Michigan University, Mt. Pleasant, MI, USA
- Program in Neuroscience, Central Michigan University, Mt. Pleasant, MI, USA
| | - Andrew Crane
- Field Neurosciences Laboratory for Restorative Neurology, Central Michigan University, Mt. Pleasant, MI, USA
- Program in Neuroscience, Central Michigan University, Mt. Pleasant, MI, USA
| | - Alison Twite
- Field Neurosciences Laboratory for Restorative Neurology, Central Michigan University, Mt. Pleasant, MI, USA
- Program in Neuroscience, Central Michigan University, Mt. Pleasant, MI, USA
| | - Steven A. Lowrance
- Field Neurosciences Laboratory for Restorative Neurology, Central Michigan University, Mt. Pleasant, MI, USA
- Program in Neuroscience, Central Michigan University, Mt. Pleasant, MI, USA
| | - Cheng Song
- Field Neurosciences Laboratory for Restorative Neurology, Central Michigan University, Mt. Pleasant, MI, USA
- Program in Neuroscience, Central Michigan University, Mt. Pleasant, MI, USA
| | - Gary L. Dunbar
- Field Neurosciences Laboratory for Restorative Neurology, Central Michigan University, Mt. Pleasant, MI, USA
- Program in Neuroscience, Central Michigan University, Mt. Pleasant, MI, USA
- Department of Psychology, Central Michigan University, Mt. Pleasant, MI, USA
- St. Mary's of Michigan Field Neurosciences Institute, Saginaw MI, USA
| |
Collapse
|
4
|
Rossignol J, Fink KD, Crane AT, Davis KK, Bombard MC, Clerc S, Bavar AM, Lowrance SA, Song C, Witte S, Lescaudron L, Dunbar GL. Reductions in behavioral deficits and neuropathology in the R6/2 mouse model of Huntington's disease following transplantation of bone-marrow-derived mesenchymal stem cells is dependent on passage number. Stem Cell Res Ther 2015; 6:9. [PMID: 25971780 PMCID: PMC4429666 DOI: 10.1186/scrt545] [Citation(s) in RCA: 34] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/20/2014] [Revised: 01/16/2015] [Accepted: 01/16/2015] [Indexed: 02/06/2023] Open
Abstract
Introduction Huntington’s disease (HD) is an autosomal dominant disorder caused by an expanded CAG repeat (greater than 38) on the short arm of chromosome 4, resulting in loss and dysfunction of neurons in the neostriatum and cortex, leading to cognitive decline, motor dysfunction, and death, typically occurring 15 to 20 years after the onset of motor symptoms. Although an effective treatment for HD has remained elusive, current studies using transplants of bone-marrow-derived mesenchymal stem cells provides considerable promise. This study further investigates the efficacy of these transplants with a focus on comparing how passage number of these cells may affect subsequent efficacy following transplantation. Methods In this study, mesenchymal stem cells isolated from the bone-marrow of mice (BM MSCs), were labeled with Hoechst after low (3 to 8) or high (40 to 50) numbers of passages and then transplanted intrastriatally into 5-week-old R6/2 mice, which carries the N-terminal fragment of the human HD gene (145 to 155 repeats) and rapidly develops symptoms analogous to the human form of the disease. Results It was observed that the transplanted cells survived and the R6/2 mice displayed significant behavioral and morphological sparing compared to untreated R6/2 mice, with R6/2 mice receiving high passage BM MSCs displaying fewer deficits than those receiving low-passage BM MSCs. These beneficial effects are likely due to trophic support, as an increase in brain derived neurotrophic factor mRNA expression was observed in the striatum following transplantation of BM MSCs. Conclusion The results from this study demonstrate that BM MSCs hold significant therapeutic value for HD, and that the amount of time the cells are exposed to in vitro culture conditions can alter their efficacy.
Collapse
Affiliation(s)
- Julien Rossignol
- Field Neurosciences Laboratory for Restorative Neurology, Brain Research and Integrative Neuroscience Center, Program in Neuroscience, 1280 East Campus Drive, HP Building Room 2336, Mount Pleasant, MI, 48859, USA. .,College of Medicine, Central Michigan University, Mount Pleasant, MI, 48859, USA.
| | - Kyle D Fink
- Field Neurosciences Laboratory for Restorative Neurology, Brain Research and Integrative Neuroscience Center, Program in Neuroscience, 1280 East Campus Drive, HP Building Room 2336, Mount Pleasant, MI, 48859, USA. .,Faculté des Science et des Techniques, Université de Nantes, 44300, Nantes, France. .,INSERM U1064, ITUN, 44093, Nantes, France.
| | - Andrew T Crane
- Field Neurosciences Laboratory for Restorative Neurology, Brain Research and Integrative Neuroscience Center, Program in Neuroscience, 1280 East Campus Drive, HP Building Room 2336, Mount Pleasant, MI, 48859, USA.
| | - Kendra K Davis
- Field Neurosciences Laboratory for Restorative Neurology, Brain Research and Integrative Neuroscience Center, Program in Neuroscience, 1280 East Campus Drive, HP Building Room 2336, Mount Pleasant, MI, 48859, USA.
| | - Matthew C Bombard
- Field Neurosciences Laboratory for Restorative Neurology, Brain Research and Integrative Neuroscience Center, Program in Neuroscience, 1280 East Campus Drive, HP Building Room 2336, Mount Pleasant, MI, 48859, USA.
| | - Steven Clerc
- Field Neurosciences Laboratory for Restorative Neurology, Brain Research and Integrative Neuroscience Center, Program in Neuroscience, 1280 East Campus Drive, HP Building Room 2336, Mount Pleasant, MI, 48859, USA.
| | - Angela M Bavar
- Field Neurosciences Laboratory for Restorative Neurology, Brain Research and Integrative Neuroscience Center, Program in Neuroscience, 1280 East Campus Drive, HP Building Room 2336, Mount Pleasant, MI, 48859, USA.
| | - Steven A Lowrance
- Field Neurosciences Laboratory for Restorative Neurology, Brain Research and Integrative Neuroscience Center, Program in Neuroscience, 1280 East Campus Drive, HP Building Room 2336, Mount Pleasant, MI, 48859, USA.
| | - Cheng Song
- Field Neurosciences Laboratory for Restorative Neurology, Brain Research and Integrative Neuroscience Center, Program in Neuroscience, 1280 East Campus Drive, HP Building Room 2336, Mount Pleasant, MI, 48859, USA.
| | - Steven Witte
- Field Neurosciences Laboratory for Restorative Neurology, Brain Research and Integrative Neuroscience Center, Program in Neuroscience, 1280 East Campus Drive, HP Building Room 2336, Mount Pleasant, MI, 48859, USA.
| | - Laurent Lescaudron
- Faculté des Science et des Techniques, Université de Nantes, 44300, Nantes, France. .,INSERM U791, Laboratoire d'Ingenierie Osteo-Articulaire et Dentaire (LIOAD), 44042, Nantes, France.
| | - Gary L Dunbar
- Field Neurosciences Laboratory for Restorative Neurology, Brain Research and Integrative Neuroscience Center, Program in Neuroscience, 1280 East Campus Drive, HP Building Room 2336, Mount Pleasant, MI, 48859, USA. .,Field Neurosciences Institute, Saginaw, MI, 48604, USA.
| |
Collapse
|
5
|
Ariga T. Pathogenic role of ganglioside metabolism in neurodegenerative diseases. J Neurosci Res 2014; 92:1227-42. [PMID: 24903509 DOI: 10.1002/jnr.23411] [Citation(s) in RCA: 35] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/20/2013] [Revised: 04/09/2014] [Accepted: 04/09/2014] [Indexed: 12/13/2022]
Abstract
Ganglioside metabolism is altered in several neurodegenerative diseases, and this may participate in several events related to the pathogenesis of these diseases. Most changes occur in specific areas of the brain and their distinct membrane microdomains or lipid rafts. Antiganglioside antibodies may be involved in dysfunction of the blood-brain barrier and disease progression in these diseases. In lipid rafts, interactions of glycosphingolipids, including ganglioside, with proteins may be responsible for the misfolding events that cause the fibril and/or aggregate processing of disease-specific proteins, such as α-synuclein, in Parkinson's disease, huntingtin protein in Huntington's disease, and copper-zinc superoxide dismutase in amyotrophic lateral sclerosis. Targeting ganglioside metabolism may represent an underexploited opportunity to design novel therapeutic strategies for neurodegeneration in these diseases.
Collapse
Affiliation(s)
- Toshio Ariga
- Institute of Molecular Medicine and Genetics, Institute of Neuroscience, Medical College of Georgia, Georgia Regents University, Augusta, Georgia
| |
Collapse
|
6
|
Fink KD, Crane AT, Lévêque X, Dues DJ, Huffman LD, Moore AC, Story DT, Dejonge RE, Antcliff A, Starski PA, Lu M, Lescaudron L, Rossignol J, Dunbar GL. Intrastriatal transplantation of adenovirus-generated induced pluripotent stem cells for treating neuropathological and functional deficits in a rodent model of Huntington's disease. Stem Cells Transl Med 2014; 3:620-31. [PMID: 24657963 DOI: 10.5966/sctm.2013-0151] [Citation(s) in RCA: 28] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/23/2022] Open
Abstract
Induced pluripotent stem cells (iPSCs) show considerable promise for cell replacement therapies for Huntington's disease (HD). Our laboratory has demonstrated that tail-tip fibroblasts, reprogrammed into iPSCs via two adenoviruses, can survive and differentiate into neuronal lineages following transplantation into healthy adult rats. However, the ability of these cells to survive, differentiate, and restore function in a damaged brain is unknown. To this end, adult rats received a regimen of 3-nitropropionic acid (3-NP) to induce behavioral and neuropathological deficits that resemble HD. At 7, 21, and 42 days after the initiation of 3-NP or vehicle, the rats received intrastriatal bilateral transplantation of iPSCs. All rats that received 3-NP and vehicle treatment displayed significant motor impairment, whereas those that received iPSC transplantation after 3-NP treatment had preserved motor function. Histological analysis of the brains of these rats revealed significant decreases in optical densitometric measures in the striatum, lateral ventricle enlargement, as well as an increase in striosome size in all rats receiving 3-NP when compared with sham rats. The 3-NP-treated rats given transplants of iPSCs in the 7- or 21-day groups did not exhibit these deficits. Transplantation of iPSCs at the late-stage (42-day) time point did not protect against the 3-NP-induced neuropathology, despite preserving motor function. Transplanted iPSCs were found to survive and differentiate into region-specific neurons in the striatum of 3-NP rats, at all transplantation time points. Taken together, these results suggest that transplantation of adenovirus-generated iPSCs may provide a potential avenue for therapeutic treatment of HD.
Collapse
Affiliation(s)
- Kyle D Fink
- Field Neurosciences Institute Laboratory for Restorative Neurology, Brain Research and Integrative Neuroscience Center, Program in Neuroscience, and College of Medicine, Central Michigan University, Mount Pleasant, Michigan, USA; Faculté des Sciences et des Techniques, Faculté de Médecine, and Faculté d'Odontologie, Université de Nantes, Nantes, France; INSERM U1064, ITUN, Nantes, France; INSERM U791, Laboratoire d'Ingenierie Osteo-Articulaire et Dentaire, Nantes, France; INSERM UMR 643, Nantes, France; Field Neurosciences Institute, Saginaw, Michigan, USA; Centre Hospitalier-Universitaire Hotel Dieu de Nantes, Nantes, France
| | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
7
|
Rossignol J, Fink K, Davis K, Clerc S, Crane A, Matchynski J, Lowrance S, Bombard M, DeKorver N, Lescaudron L, Dunbar GL. Transplants of Adult Mesenchymal and Neural Stem Cells Provide Neuroprotection and Behavioral Sparing in a Transgenic Rat Model of Huntington's Disease. Stem Cells 2014; 32:500-9. [DOI: 10.1002/stem.1508] [Citation(s) in RCA: 47] [Impact Index Per Article: 4.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/13/2012] [Revised: 07/16/2013] [Accepted: 07/27/2013] [Indexed: 02/06/2023]
Affiliation(s)
- Julien Rossignol
- Department of Psychology; Central Michigan University; Mount Pleasant Michigan USA
- Program in Neuroscience; Central Michigan University; Mount Pleasant Michigan USA
- College of Medicine; Central Michigan University; Mount Pleasant Michigan USA
- Field Neurosciences Institute; Saginaw Michigan USA
| | - Kyle Fink
- Program in Neuroscience; Central Michigan University; Mount Pleasant Michigan USA
| | - Kendra Davis
- Program in Neuroscience; Central Michigan University; Mount Pleasant Michigan USA
| | - Steven Clerc
- Program in Neuroscience; Central Michigan University; Mount Pleasant Michigan USA
| | - Andrew Crane
- Program in Neuroscience; Central Michigan University; Mount Pleasant Michigan USA
| | - Jessica Matchynski
- Program in Neuroscience; Central Michigan University; Mount Pleasant Michigan USA
| | - Steven Lowrance
- Program in Neuroscience; Central Michigan University; Mount Pleasant Michigan USA
| | - Matthew Bombard
- Program in Neuroscience; Central Michigan University; Mount Pleasant Michigan USA
| | - Nicholas DeKorver
- Program in Neuroscience; Central Michigan University; Mount Pleasant Michigan USA
| | - Laurent Lescaudron
- INSERM UMR 643; Nantes France
- ITUN, Institut Transplantation Urologie Nephrologie; CHU Nantes France
- Université de Nantes; UFR des Sciences et des Techniques; Nantes France
| | - Gary L. Dunbar
- Department of Psychology; Central Michigan University; Mount Pleasant Michigan USA
- Program in Neuroscience; Central Michigan University; Mount Pleasant Michigan USA
- College of Medicine; Central Michigan University; Mount Pleasant Michigan USA
- Field Neurosciences Institute; Saginaw Michigan USA
| |
Collapse
|
8
|
Assi E, Cazzato D, De Palma C, Perrotta C, Clementi E, Cervia D. Sphingolipids and brain resident macrophages in neuroinflammation: an emerging aspect of nervous system pathology. Clin Dev Immunol 2013; 2013:309302. [PMID: 24078816 PMCID: PMC3775448 DOI: 10.1155/2013/309302] [Citation(s) in RCA: 38] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/23/2013] [Accepted: 08/01/2013] [Indexed: 12/25/2022]
Abstract
Sphingolipid metabolism is deeply regulated along the differentiation and development of the central nervous system (CNS), and the expression of a peculiar spatially and temporarily regulated sphingolipid pattern is essential for the maintenance of the functional integrity of the nervous system. Microglia are resident macrophages of the CNS involved in general maintenance of neural environment. Modulations in microglia phenotypes may contribute to pathogenic forms of inflammation. Since defects in macrophage/microglia activity contribute to neurodegenerative diseases, it will be essential to systematically identify the components of the microglial cell response that contribute to disease progression. In such complex processes, the sphingolipid systems have recently emerged to play important roles, thus appearing as a key new player in CNS disorders. This review provides a rationale for harnessing the sphingolipid metabolic pathway as a potential target against neuroinflammation.
Collapse
Affiliation(s)
- Emma Assi
- Department of Biomedical and Clinical Sciences, Unit of Clinical Pharmacology, CNR Institute of Neuroscience, “Luigi Sacco” University Hospital, University of Milan, 20157 Milan, Italy
| | - Denise Cazzato
- Department of Biomedical and Clinical Sciences, Unit of Clinical Pharmacology, CNR Institute of Neuroscience, “Luigi Sacco” University Hospital, University of Milan, 20157 Milan, Italy
| | - Clara De Palma
- Department of Biomedical and Clinical Sciences, Unit of Clinical Pharmacology, CNR Institute of Neuroscience, “Luigi Sacco” University Hospital, University of Milan, 20157 Milan, Italy
| | - Cristiana Perrotta
- Department of Biomedical and Clinical Sciences, Unit of Clinical Pharmacology, CNR Institute of Neuroscience, “Luigi Sacco” University Hospital, University of Milan, 20157 Milan, Italy
| | - Emilio Clementi
- Department of Biomedical and Clinical Sciences, Unit of Clinical Pharmacology, CNR Institute of Neuroscience, “Luigi Sacco” University Hospital, University of Milan, 20157 Milan, Italy
- E. Medea Scientific Institute, 23842 Bosisio Parini, Italy
| | - Davide Cervia
- Department of Biomedical and Clinical Sciences, Unit of Clinical Pharmacology, CNR Institute of Neuroscience, “Luigi Sacco” University Hospital, University of Milan, 20157 Milan, Italy
- Department for Innovation in Biological, Agro-Food and Forest Systems (DIBAF), University of Tuscia, 01100 Viterbo, Italy
| |
Collapse
|
9
|
Abstract
Huntington's disease (HD) is an inherited neurodegenerative disease that is characterized by movement abnormalities, cognitive impairment, and abnormal behavior as well as sleep and weight problems. It is an autosomal dominant disorder caused by a mutation in the huntingtin gene on the short arm of chromosome 4, which results in the progressive degeneration of the basal ganglia (caudate, putamen, and globus pallidus), cerebral cortex, brainstem, thalamus, and hypothalamus. This chapter considers four avenues of research: (a) the restoration of neurogenesis as an endogenous cell therapy in HD, (b) fetal tissue transplantation, (c) stem cell transplantation, and finally (d) the use of endogenous trophic factors such as brain derived neurotrophic factor.
Collapse
|
10
|
Lescaudron L, Boyer C, Bonnamain V, Fink KD, Lévêque X, Rossignol J, Nerrière-Daguin V, Malouet AC, Lelan F, Dey ND, Michel-Monigadon D, Lu M, Neveu I, von Hörsten S, Naveilhan P, Dunbar GL. Assessing the potential clinical utility of transplantations of neural and mesenchymal stem cells for treating neurodegenerative diseases. Methods Mol Biol 2012; 879:147-64. [PMID: 22610559 DOI: 10.1007/978-1-61779-815-3_10] [Citation(s) in RCA: 16] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/05/2023]
Abstract
Treatments for neurodegenerative diseases have little impact on the long-term patient health. However, cellular transplants of neuroblasts derived from the aborted embryonic brain tissue in animal models of neurodegenerative disorders and in patients have demonstrated survival and functionality in the brain. However, ethical and functional problems due to the use of this fetal tissue stopped most of the clinical trials. Therefore, new cell sources were needed, and scientists focused on neural (NSCs) and mesenchymal stem cells (MSCs). When transplanted in the brain of animals with Parkinson's or Huntington's disease, NSCs and MSCs were able to induce partial functional recovery by promoting neuroprotection and immunomodulation. MSCs are more readily accessible than NSCs due to sources such as the bone marrow. However, MSCs are not capable of differentiating into neurons in vivo where NSCs are. Thus, transplantation of NSCs and MSCs is interesting for brain regenerative medicine. In this chapter, we detail the methods for NSCs and MSCs isolation as well as the transplantation procedures used to treat rodent models of neurodegenerative damage.
Collapse
|
11
|
Intrastriatal transplantation of neurotrophic factor-secreting human mesenchymal stem cells improves motor function and extends survival in R6/2 transgenic mouse model for Huntington's disease. PLOS CURRENTS 2012; 4:e4f7f6dc013d4e. [PMID: 22953237 PMCID: PMC3426086 DOI: 10.1371/4f7f6dc013d4e] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Figures] [Subscribe] [Scholar Register] [Indexed: 01/20/2023]
Abstract
Stem cell-based treatment for Huntington's disease (HD) is an expanding field of research. Although various stem cells have been shown to be beneficial in vivo, no long standing clinical effect has been demonstrated. To address this issue, we are developing a stem cell-based therapy designed to improve the microenvironment of the diseased tissue via delivery of neurotrophic factors (NTFs). Previously, we established that bone marrow derived human mesenchymal stem cells (MSCs) can be differentiated using medium based cues into NTF-secreting cells (NTF+ cells) that express astrocytic markers. NTF+ cells were shown to alleviate neurodegeneration symptoms in several disease models in vitro and in vivo, including the model for excitotoxicity. In the present study, we explored if the timing of intrastriatal transplantation of hNTF+ cells into the R6/2 transgenic mouse model for HD influences motor function and survival. One hundred thousand cells were transplanted bilaterally into the striatum of immune-suppressed mice at 4.5, 5.5 and 6.5 weeks of age. Contrary to our expectations, early transplantation of NTF+ cells did not improve motor function or overall survival. However, late (6.5 weeks) transplantation resulted in a temporary improvement in motor function and an extension of life span relative to that observed for PBS treated mice. We conclude that late transplantation of NTF+ cells induces a beneficial effect in this transgenic model for HD. Since no transplanted NTF+ cells could be detected in vivo, we suspect that the temporary nature of the beneficial effect is due to poor survival of transplanted cells. In general, we submit that NTF+ cells should be further evaluated for the therapy of HD.
Collapse
|
12
|
Lowrance S, Matchynski J, Rossignol J, Dekorver N, Sandstrom M, Dunbar G. CXB-909 Attenuates Cognitive Deficits in the Mu-P-75 Saporin Mouse Model of Alzheimer’s Disease. ACTA ACUST UNITED AC 2012. [DOI: 10.4236/nm.2012.31010] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]
|
13
|
Starossom SC, Imitola J, Wang Y, Cao L, Khoury SJ. Subventricular zone microglia transcriptional networks. Brain Behav Immun 2011; 25:991-9. [PMID: 21074605 PMCID: PMC3109092 DOI: 10.1016/j.bbi.2010.11.002] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 07/19/2010] [Revised: 11/03/2010] [Accepted: 11/03/2010] [Indexed: 01/19/2023] Open
Abstract
Microglia play an important role in inflammatory diseases of the central nervous system. There is evidence of microglial diversity with distinct phenotypes exhibiting either neuroprotection and repair or neurotoxicity. However the precise molecular mechanisms underlying this diversity are still unknown. Using a model of experimental autoimmune encephalomyelitis (EAE) we performed transcriptional profiling of isolated subventricular zone microglia from the acute and chronic disease phases of EAE. We found that microglia exhibit disease phase specific gene expression signatures, that correspond to unique gene ontology functions and genomic networks. Our data demonstrate for the first time, distinct transcriptional networks of microglia activation in vivo, that suggests a role as mediators of injury or repair.
Collapse
Affiliation(s)
- Sarah C. Starossom
- Center for Neurologic Diseases, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA 02115 USA
| | - Jaime Imitola
- Center for Neurologic Diseases, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA 02115 USA
| | - Yue Wang
- Center for Neurologic Diseases, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA 02115 USA
| | - Li Cao
- Center for Neurologic Diseases, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA 02115 USA
| | - Samia J. Khoury
- Center for Neurologic Diseases, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA 02115 USA
| |
Collapse
|
14
|
Prinetti A, Prioni S, Chiricozzi E, Schuchman EH, Chigorno V, Sonnino S. Secondary Alterations of Sphingolipid Metabolism in Lysosomal Storage Diseases. Neurochem Res 2011; 36:1654-68. [DOI: 10.1007/s11064-010-0380-3] [Citation(s) in RCA: 28] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 12/20/2010] [Indexed: 12/20/2022]
|
15
|
Rossignol J, Boyer C, Lévèque X, Fink KD, Thinard R, Blanchard F, Dunbar GL, Lescaudron L. Mesenchymal stem cell transplantation and DMEM administration in a 3NP rat model of Huntington's disease: morphological and behavioral outcomes. Behav Brain Res 2010; 217:369-78. [PMID: 21070819 DOI: 10.1016/j.bbr.2010.11.006] [Citation(s) in RCA: 60] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/09/2010] [Revised: 10/27/2010] [Accepted: 11/01/2010] [Indexed: 01/24/2023]
Abstract
Transplantation of mesenchymal stem cells (MSCs) may offer a viable treatment for Huntington's disease (HD). We tested the efficacy of MSC transplants to reduce deficits in a 3-nitropropionic acid (3NP) rat model of HD. Five groups of rats (Sham, 3NP, 3NP+vehicle, 3NP+TP(low), 3NP+TP(high)), were given PBS or 3NP intraperitoneally, twice daily for 42 days. On day 28, rats in all groups except Sham and 3NP, received intrastriatal injections of either 200,000 MSCs (TP(low)), 400,000 (TP(high)) MSCs or DMEM (VH, the vehicle for transplantation). MSCs survived 72 days without inducing a strong inflammatory response from the striatum. Behavioral sparing was observed on tests of supported-hindlimb-retraction, unsupported-hindlimb-retraction, visual paw placement and stepping ability for 3NP+TP(low) rats and on the unsupported-hindlimb-retraction and rotarod tasks for 3NP+VH rats. Relative to 3NP controls, all treated groups were protected from 3NP-induced enlargement of the lateral ventricles. In vitro, MSCs expressed transcripts for numerous neurotrophic factors. In vivo, increased striatal labeling in BDNF, collagen type-I and fibronectin (but not GDNF or CNTF) was observed in the brains of MSC-transplanted rats but not in DMEM-treated rats. In addition, none of the transplanted MSCs expressed neural phenotypes. These findings suggest that factors other than neuronal replacement underlie the behavioral sparing observed in 3NP rats after MSC transplantation.
Collapse
|
16
|
Dey ND, Bombard MC, Roland BP, Davidson S, Lu M, Rossignol J, Sandstrom MI, Skeel RL, Lescaudron L, Dunbar GL. Genetically engineered mesenchymal stem cells reduce behavioral deficits in the YAC 128 mouse model of Huntington's disease. Behav Brain Res 2010; 214:193-200. [PMID: 20493905 DOI: 10.1016/j.bbr.2010.05.023] [Citation(s) in RCA: 113] [Impact Index Per Article: 8.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/05/2010] [Revised: 05/07/2010] [Accepted: 05/12/2010] [Indexed: 12/13/2022]
Abstract
The purpose of this study was to evaluate the therapeutic effects of the transplantation of bone-marrow mesenchymal stem cells (MSCs), genetically engineered to over-express brain-derived neurotrophic factor (BDNF) or nerve growth factor (NGF) on motor deficits and neurodegeneration in YAC 128 transgenic mice. MSCs, harvested from mouse femurs, were genetically engineered to over-express BDNF and/or NGF and these cells, or the vehicle solution, were injected into the striata of four-month old YAC 128 transgenic and wild-type mice. Assessments of motor ability on the rotarod and the severity of clasping were made one day prior to transplantation and once monthly, thereafter, to determine the effects of the transplanted cells on motor function. The mice were sacrificed at 13-months of age for immunohistological examination. All YAC 128 mice receiving transplants had reduced clasping, relative to vehicle-treated YAC 128 mice, while YAC 128 mice that were transplanted with MSCs which were genetically engineered to over-express BDNF, had the longest latencies on the rotarod and the least amount of neuronal loss within the striatum of the YAC 128 mice. These results indicate that intrastriatal transplantation of MSCs that over-express BDNF may create an environment within the striatum that slows neurodegenerative processes and provides behavioral sparing in the YAC 128 mouse model of HD. Further research on the long-term safety and efficacy of this approach is needed before its potential clinical utility can be comprehensively assessed.
Collapse
Affiliation(s)
- Nicholas D Dey
- Field Neurosciences Institute Laboratory for Restorative Neurology, Central Michigan University, Mt. Pleasant, MI 48858, USA
| | | | | | | | | | | | | | | | | | | |
Collapse
|
17
|
Huang H, Chen L, Sanberg P. Cell Therapy From Bench to Bedside Translation in CNS Neurorestoratology Era. CELL MEDICINE 2010; 1:15-46. [PMID: 21359168 DOI: 10.3727/215517910x516673] [Citation(s) in RCA: 46] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/13/2022]
Abstract
Recent advances in cell biology, neural injury and repair, and the progress towards development of neurorestorative interventions are the basis for increased optimism. Based on the complexity of the processes of demyelination and remyelination, degeneration and regeneration, damage and repair, functional loss and recovery, it would be expected that effective therapeutic approaches will require a combination of strategies encompassing neuroplasticity, immunomodulation, neuroprotection, neurorepair, neuroreplacement, and neuromodulation. Cell-based restorative treatment has become a new trend, and increasing data worldwide have strongly proven that it has a pivotal therapeutic value in CNS disease. Moreover, functional neurorestoration has been achieved to a certain extent in the CNS clinically. Up to now, the cells successfully used in preclinical experiments and/or clinical trial/treatment include fetal/embryonic brain and spinal cord tissue, stem cells (embryonic stem cells, neural stem/progenitor cells, hematopoietic stem cells, adipose-derived adult stem/precursor cells, skin-derived precursor, induced pluripotent stem cells), glial cells (Schwann cells, oligodendrocyte, olfactory ensheathing cells, astrocytes, microglia, tanycytes), neuronal cells (various phenotypic neurons and Purkinje cells), mesenchymal stromal cells originating from bone marrow, umbilical cord, and umbilical cord blood, epithelial cells derived from the layer of retina and amnion, menstrual blood-derived stem cells, Sertoli cells, and active macrophages, etc. Proof-of-concept indicates that we have now entered a new era in neurorestoratology.
Collapse
Affiliation(s)
- Hongyun Huang
- Center for Neurorestoratology, Beijing Rehabilitation Center, Beijing, P.R. China
| | | | | |
Collapse
|
18
|
Piccinini M, Scandroglio F, Prioni S, Buccinnà B, Loberto N, Aureli M, Chigorno V, Lupino E, DeMarco G, Lomartire A, Rinaudo MT, Sonnino S, Prinetti A. Deregulated sphingolipid metabolism and membrane organization in neurodegenerative disorders. Mol Neurobiol 2010; 41:314-40. [PMID: 20127207 DOI: 10.1007/s12035-009-8096-6] [Citation(s) in RCA: 98] [Impact Index Per Article: 7.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/05/2009] [Accepted: 12/22/2009] [Indexed: 12/13/2022]
Abstract
Sphingolipids are polar membrane lipids present as minor components in eukaryotic cell membranes. Sphingolipids are highly enriched in nervous cells, where they exert important biological functions. They deeply affect the structural and geometrical properties and the lateral order of cellular membranes, modulate the function of several membrane-associated proteins, and give rise to important intra- and extracellular lipid mediators. Sphingolipid metabolism is regulated along the differentiation and development of the nervous system, and the expression of a peculiar spatially and temporarily regulated sphingolipid pattern is essential for the maintenance of the functional integrity of the nervous system: sphingolipids in the nervous system participate to several signaling pathways controlling neuronal survival, migration, and differentiation, responsiveness to trophic factors, synaptic stability and synaptic transmission, and neuron-glia interactions, including the formation and stability of central and peripheral myelin. In several neurodegenerative diseases, sphingolipid metabolism is deeply deregulated, leading to the expression of abnormal sphingolipid patterns and altered membrane organization that participate to several events related to the pathogenesis of these diseases. The most impressive consequence of this deregulation is represented by anomalous sphingolipid-protein interactions that are at least, in part, responsible for the misfolding events that cause the fibrillogenic and amyloidogenic processing of disease-specific protein isoforms, such as amyloid beta peptide in Alzheimer's disease, huntingtin in Huntington's disease, alpha-synuclein in Parkinson's disease, and prions in transmissible encephalopathies. Targeting sphingolipid metabolism represents today an underexploited but realistic opportunity to design novel therapeutic strategies for the intervention in these diseases.
Collapse
Affiliation(s)
- Marco Piccinini
- Section of Biochemistry, Department of Medicine and Experimental Oncology, University of Turin, Turin, Italy
| | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
19
|
Rossignol J, Boyer C, Thinard R, Remy S, Dugast A, Dubayle D, Dey ND, Boeffard F, Delecrin J, Heymann D, Vanhove B, Anegon I, Naveilhan P, Dunbar GL, Lescaudron L. Mesenchymal stem cells induce a weak immune response in the rat striatum after allo or xenotransplantation. J Cell Mol Med 2009. [DOI: 10.1111/j.1582-4934.2008.00657.x] [Citation(s) in RCA: 68] [Impact Index Per Article: 4.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/29/2022] Open
Affiliation(s)
- Julien Rossignol
- INSERM UMR 643, Nantes, France
- ITERT, Institut de Transplantation et de Recherche en Transplantation, CHU, Nantes, France
- Université de Nantes, Faculté de Médecine, Nantes, France
- Field Neurosciences Institute, Saginaw, MI, USA
- Department of Psychology and Program in Neuroscience, Central Michigan University, MI, USA
| | - Cécile Boyer
- INSERM UMR 643, Nantes, France
- ITERT, Institut de Transplantation et de Recherche en Transplantation, CHU, Nantes, France
- Université de Nantes, Faculté de Médecine, Nantes, France
| | - Reynald Thinard
- INSERM UMR 643, Nantes, France
- ITERT, Institut de Transplantation et de Recherche en Transplantation, CHU, Nantes, France
| | - Séverine Remy
- INSERM UMR 643, Nantes, France
- ITERT, Institut de Transplantation et de Recherche en Transplantation, CHU, Nantes, France
| | - Anne‐Sophie Dugast
- INSERM UMR 643, Nantes, France
- ITERT, Institut de Transplantation et de Recherche en Transplantation, CHU, Nantes, France
- Université de Nantes, Faculté de Médecine, Nantes, France
| | - David Dubayle
- Université Paris Descartes, UFR Biomédicale des Saints‐Pères, CNRS UMR, Paris, France
| | - Nicolas D. Dey
- Field Neurosciences Institute, Saginaw, MI, USA
- Department of Psychology and Program in Neuroscience, Central Michigan University, MI, USA
| | - Françoise Boeffard
- INSERM UMR 643, Nantes, France
- ITERT, Institut de Transplantation et de Recherche en Transplantation, CHU, Nantes, France
- Université de Nantes, Faculté de Médecine, Nantes, France
| | - Joël Delecrin
- Service de Chirurgie Orthopédique, CHU, Nantes, France
| | | | - Bernard Vanhove
- INSERM UMR 643, Nantes, France
- ITERT, Institut de Transplantation et de Recherche en Transplantation, CHU, Nantes, France
- Université de Nantes, Faculté de Médecine, Nantes, France
| | - Ignacio Anegon
- INSERM UMR 643, Nantes, France
- ITERT, Institut de Transplantation et de Recherche en Transplantation, CHU, Nantes, France
- Université de Nantes, Faculté de Médecine, Nantes, France
| | - Philippe Naveilhan
- INSERM UMR 643, Nantes, France
- ITERT, Institut de Transplantation et de Recherche en Transplantation, CHU, Nantes, France
- Université de Nantes, Faculté de Médecine, Nantes, France
| | - Gary L. Dunbar
- Field Neurosciences Institute, Saginaw, MI, USA
- Department of Psychology and Program in Neuroscience, Central Michigan University, MI, USA
| | - Laurent Lescaudron
- INSERM UMR 643, Nantes, France
- ITERT, Institut de Transplantation et de Recherche en Transplantation, CHU, Nantes, France
- Université de Nantes, Faculté de Médecine, Nantes, France
- Université de Nantes, UFR des Sciences et des Techniques, Nantes, France
| |
Collapse
|
20
|
Ren Zheng MM, Gongping Li BME, Hao He MM, Yinghe Lin MD. Bionic dental pulp: its potential value following root canal therapy. Med Hypotheses 2008; 72:129-30. [PMID: 18986772 DOI: 10.1016/j.mehy.2008.09.029] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/30/2008] [Revised: 08/30/2008] [Accepted: 09/12/2008] [Indexed: 10/21/2022]
Abstract
Dental pulp can provide nutrition for teeth. The teeth after root canal therapy without pulp will turn frailer because of dehydration, and it may be easily broken. Bionic dental pulp possesses similar components of the healthy dental pulp. So we put forward a hypothesis that bionic dental pulp can be filled into root canals to provide nutrition for teeth like healthy pulp. Then the life-span of teeth after root canal therapy could increase.
Collapse
Affiliation(s)
- M M Ren Zheng
- Department of Prosthetics, West China College of Stomatology, Chengdu, Sichuan 610041, China
| | | | | | | |
Collapse
|
21
|
Desplats PA, Denny CA, Kass KE, Gilmartin T, Head SR, Sutcliffe JG, Seyfried TN, Thomas EA. Glycolipid and ganglioside metabolism imbalances in Huntington's disease. Neurobiol Dis 2007; 27:265-77. [PMID: 17600724 PMCID: PMC2082128 DOI: 10.1016/j.nbd.2007.05.003] [Citation(s) in RCA: 81] [Impact Index Per Article: 4.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/12/2007] [Revised: 05/03/2007] [Accepted: 05/07/2007] [Indexed: 10/23/2022] Open
Abstract
We have explored genome-wide expression of genes related to glycobiology in exon 1 transgenic Huntington's disease (HD) mice using a custom-designed GLYCOv2 chip and Affymetrix microarray analyses. We validated, using quantitative real-time PCR, abnormal expression levels of genes encoding glycosyltransferases in the striatum of R6/1 transgenic mice, as well as in postmortem caudate from human HD subjects. Many of these genes show differential regional expression within the CNS, as indicated by in situ hybridization analysis, suggesting region-specific regulation of this system in the brain. We further show disrupted patterns of glycolipids (acidic and neutral lipids) and/or ganglioside levels in both the forebrain of the R6/1 transgenic mice and caudate samples from human HD subjects. These findings reveal novel disruptions in glycolipid/ganglioside metabolic pathways in the pathology of HD and suggest that the development of new targets to restore glycosphingolipid balance may act to ameliorate some symptoms of HD.
Collapse
Affiliation(s)
- Paula A. Desplats
- Department of Molecular Biology, The Scripps Research Institute, La Jolla, California, USA
| | - Christine A. Denny
- Department of Biology, Boston College, Chestnut Hill, Massachusetts, USA
| | - Kristi E. Kass
- Department of Molecular Biology, The Scripps Research Institute, La Jolla, California, USA
| | - Tim Gilmartin
- Department of Research Services, The Scripps Research Institute, La Jolla, California, USA
| | - Steven R. Head
- Department of Research Services, The Scripps Research Institute, La Jolla, California, USA
| | - J. Gregor Sutcliffe
- Department of Molecular Biology, The Scripps Research Institute, La Jolla, California, USA
| | - Thomas N. Seyfried
- Department of Biology, Boston College, Chestnut Hill, Massachusetts, USA
| | - Elizabeth A. Thomas
- Department of Molecular Biology, The Scripps Research Institute, La Jolla, California, USA
| |
Collapse
|
22
|
Liu CT, Yang YJ, Yin F, Wang X, Yu XH, Wang QH, Wang XL, Xie M. The immunobiological development of human bone marrow mesenchymal stem cells in the course of neuronal differentiation. Cell Immunol 2006; 244:19-32. [PMID: 17448455 DOI: 10.1016/j.cellimm.2007.02.003] [Citation(s) in RCA: 16] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/25/2006] [Revised: 01/26/2007] [Accepted: 02/07/2007] [Indexed: 11/23/2022]
Abstract
The central nervous system (CNS) has been referred to as the "immunological privileged site". However, it is now clear that the privileged status of the CNS is a result of a balance between immune privilege and effective response. In vitro, human bone marrow mesenchymal stem cells (MSCs) have the ability to differentiate into neurons. Based on this biological attribute we gain the possibility by means of using MSCs as the donors to develop a future cell therapy in clinical application. But using MSCs as donor cells inevitably raises the question as to whether these donor cells would be immunogenic, and if so, would they be rejected after transplantation. To investigate this, human MSCs were cultured in vitro and induced to differentiate along neuronal lineage. The expression of human leukocyte antigen (HLA) class I and class II molecules and the co-stimulatory protein CD80 were increased on the surface of MSCs in the course of neuronal differentiation. But neither of the co-stimulatory proteins, CD40 or CD86, was expressed. After IFN-gamma exposure, the expression of the HLA molecules was further enhanced, but the co-stimulatory proteins were unaffected. MSCs that had been differentiated along neuronal lineage were not capable of inducing the proliferation of peripheral blood lymphocytes (PBLs). Even after IFN-gamma exposure, PBLs remained unresponsive. Furthermore, MSCs differentiated along neuronal lineage suppressed the proliferation of PBLs induced by allogeneic PBLs and mitogens. The mechanisms involved in the immunosuppression may be related to the effect of soluble factors and cell-cell interactions of neuronal differentiated MSCs and PBLs. From the above data we suggested that the low immunogenicity and immunomodulatory function of MSCs in the course of neuronal differentiation in vitro, which will be helpful to further investigation in order to establish the new way for future medical application.
Collapse
Affiliation(s)
- Chen-Tao Liu
- XiangYa Hospital, Central South University 87 Xiangya Road, Changsha, Hunan 410008, China
| | | | | | | | | | | | | | | |
Collapse
|